文献速递核素与放射性配体治疗肿瘤 PET/CT

开发带有白蛋白结合基团的放射性诊疗探针以增强砹-211(211At)的治疗效果

Development of probes for radiotheranostics with albumin binding moiety to increase the therapeutic effects of astatine-211 (211At).
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-10-11

本研究设计并合成了携带砹苯基丁酸(APBA)白蛋白结合基团的RGD肽探针[211At]5,并在正常小鼠与U-87 MG荷瘤小鼠中比较其与无白蛋白结合基团探针[67Ga]3及碘标白蛋白结合基团探针[125I]4的药代动力学与治疗效果。结果显示[211At]5血中滞留延长、肿瘤摄取与滞留显著高于[67Ga]3,并以剂量依赖方式抑制肿瘤生长;作者认为APBA具有白蛋白结合基团功能,[211At]5可作为靶向α治疗(TAT)的放射性核素治疗剂。

要点

  • APBA与IPBA一样具有白蛋白结合基团功能,可延长探针血中循环时间。
  • [211At]5的肿瘤摄取与滞留显著高于无白蛋白结合基团的[67Ga]3。
  • [211At]5以剂量依赖方式抑制U-87 MG肿瘤生长。

核心结论

  • APBA具有与IPBA类似的白蛋白结合基团功能,[211At]5作为靶向α治疗(TAT)的放射性核素治疗剂具有有用性。

研究设计与样本

  • 研究设计并合成了携带APBA的RGD肽探针[211At]5,并与无白蛋白结合基团的[67Ga]3及带IPBA的[125I]4进行对比。
  • 在正常小鼠与U-87 MG荷瘤小鼠中开展[67Ga]3、[125I]4与[211At]5的生物分布实验。
  • 向U-87 MG荷瘤小鼠给予两剂[211At]5(370或925 kBq)以确认治疗效果。

主要发现

  • [125I]4与[211At]5的血中滞留较[67Ga]3显著增加。
  • [125I]4与[211At]5呈现相似的生物分布,且肿瘤摄取与滞留显著高于[67Ga]3。
  • [211At]5以剂量依赖方式抑制肿瘤生长。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We have developed probes for multiradionuclides radiotheranostics using RGD peptide ([67Ga]Ga-DOTA-c[RGDf(4-I)K] ([67Ga]1) and Ga-DOTA-[211At]c[RGDf(4-At)K] ([211At]2)) for clinical applications. The introduction of an albumin binding moiety (ABM), such as 4-(4-iodophenyl)-butyric acid (IPBA), that has high affinity with the blood albumin and prolongs the circulation half-life can improve the pharmacokinetics of drugs. To perform more effective targeted alpha therapy (TAT), we designed and synthesized Ga-DOTA-K([211At]APBA)-c(RGDfK) ([211At]5) with 4-(4-astatophenyl)-butyric acid (APBA), which has an astato group instead of an iodo group in IPBA. We evaluated whether APBA functions as ABM and [211At]5 is effective for TAT. In addition, we prepared 67Ga-labeled RGD peptide without ABM, [67Ga]Ga-DOTA-K-c(RGDfK) ([67Ga]3), and 125I-labeled RGD peptide with ABM, Ga-DOTA-K([125I]IPBA)-c(RGDfK) ([125I]4), to compare with [211At]5. METHODS: Biodistribution experiments of [67Ga]3 without ABM, [125I]4 and [211At]5 with ABM were conducted in normal mice and U-87 MG tumor-bearing mice. In addition, two doses of [211At]5 (370 or 925 kBq) were administered to U-87 MG tumor-bearing mice to confirm the therapeutic effects. RESULTS: The blood retention of [125I]4 and [211At]5 was remarkably increased compared to [67Ga]3. Also, [125I]4 and [211At]5 showed similar biodistribution and significantly greater tumor accumulation and retention compared to [67Ga]3. In addition, [211At]5 inhibited tumor growth in a dose-dependent manner. CONCLUSION: The functionality of APBA as ABM like IPBA, and the usefulness of [211At]5 as the radionuclide therapy agent for TAT was revealed.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Echigo H, Mishiro K, Munekane M, et al. Development of probes for radiotheranostics with albumin binding moiety to increase the therapeutic effects of astatine-211 (211At). Eur J Nucl Med Mol Imaging. 2023. PMID: 37819452. doi:10.1007/s00259-023-06457-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。